Chronic myelogenous leukemia (CML) is driven by Bcr-Abl, a constitutively active protein-tyrosine kinase that stimulates proliferation ... of this mutant in the CML cell line, K562 and in TF ...

Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

6: Unmet Needs Addressed by BTKis Brian Koffman, MD, reviews how Bruton tyrosine kinase inhibitors are addressing unmet needs in chronic lymphocytic leukemia, mantle cell lymphoma, and small ...

Acute myeloid leukemia ... FLT3 mutation. The FLT3 gene manages the production of fms-like tyrosine kinase 3 (FLT3). FLT3 is a protein that manages the growth and division of various cells ...

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

HCL variant is also called splenic B-cell lymphoma with prominent nucleoli. The V600E missense mutation in the cytosolic serine–threonine kinase BRAF leads to its constitutive activation ...

EGFR is a cell surface receptor that regulates cell proliferation and belongs to a class of proteins known as receptor tyrosine ... mutant EGFR in a completely new way, not by inhibiting its ...

Tagrisso (osimertinib) has been found to be associated with positive outcomes, including improvements in overall survival, among patients with unresectable stage 3 EGFR-mutant non-small cell lung ...